Harbour BioMed Included in Stock Connect, Reflecting Market Recognition
Shares of Harbour BioMed (HKEX: 02142.HK) have been officially included in the eligible shares list for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs. This inclusion allows mainland Chinese investors to directly invest in the company, highlighting its market capitalization exceeding HK$10 billion and positioning it among large- and mid-cap biopharmaceutical firms listed on Hong Kong's stock exchange. In H1 2026, Harbour BioMed reported total revenue of approximately US$122.5 million, a year-over-year increase of 20.9%. The company also achieved adjusted net profit of around US$71.6 million for the seventh consecutive profitable half-year, demonstrating its transition to normalized profitability and validating the sustainability of its business model. The firm maintains strong financial resources with cash and equivalents totaling approximately US$359.2 million as of June 30, 2026. Its pipeline includes nearly 30 drug candidates across multiple therapeutic areas, including several in clinical trials or regulatory submission stages.
Tickers: $AZN
Topics: biopharmaceutical hkex pipeline revenue_growth stock_connect